Sponsored content brought to you by The advent of multiomic approaches has significantly improved early cancer detection by ...
In recent years, scientists have worked hard to find better ways to detect dementia, including Alzheimer's disease, long ...
Clinical Trials Arena on MSN22h
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’sA first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease ...
Scientists have for the first time looked deep into the protein structure that may determine our vision—and discovered that ...
John Beeler, Ph.D., SVP of Business Development at BPGbio, brings over two decades of experience in biotechnology and business development, with extensive expertise in novel therapeutics. Before ...
Researchers have developed a blood test based on a protein biomarker for tau tangles that can help diagnose Alzheimer’s ...
Neurodegenerative disorders have increasing incidence with limited treatment options. Approaches to target neuroinflammation in various neurodegenerative disorders, such as Alzheimer’s disease (AD), ...
Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.
A new study has shown that specific blood biomarkers could predict the onset of dementia, up to ten years before an actual ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
A new study from Sweden has found that a simple blood test may be able to predict a person’s risk of developing dementia up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback